Literature DB >> 29760596

11C-methionine positron emission tomography for target delineation of recurrent glioblastoma in re-irradiation planning.

Hidekazu Tanaka1, Takahiro Yamaguchi1, Kae Hachiya1, Kazuhiro Miwa2, Jun Shinoda2, Masahide Hayashi3, Shinichi Ogawa3, Hironori Nishibori4, Satoshi Goshima1, Masayuki Matsuo1.   

Abstract

AIM: To define the optimal margin on MRI scans in the re-radiation planning of recurrent glioblastoma using methionine positron emission tomography (MET-PET).
BACKGROUND: It would be very useful if the optimal margin on MRI to cover the uptake area on MET-PET is known.
MATERIALS AND METHODS: CT, MRI, and MET-PET were performed separately over the course of 2 weeks. Among the MRI scans, we used the contrast-enhanced T1-weighted images (Gd-MRI) and T2-weighted images (T2-MRI). The Gd-MRI-based clinical target volume (CTV) (CTV-Gd) and the T2-MRI-based CTV (CTV-T2) were defined as the contrast-enhanced area on Gd-MRI and the high intensity area on T2-MRI, respectively. We defined CTV x mm (x = 5, 10, 15, 20) as x mm outside the CTV. MET-PET-based CTV (CTV-MPET) was defined as the area of accumulation of MET-PET. We calculated the sensitivity and specificity of CTV-Gd and CTV-T2 following comparison with CTV-MPET, which served as the gold standard in this study.
RESULTS: The sensitivity of CTV-T2 5 mm (98%) was significantly higher than CTV-T2 (87%), and there was no significant difference in the sensitivity between CTV-T2 5 mm and CTV T2 10, 15, or 20 mm. The sensitivity of CTV-Gd 20 mm (97%) was lower than that of CTV-T2 5 mm (98%).
CONCLUSIONS: A margin of at least 5 mm around the high intensity area on T2-MRI is necessary in the target volume delineation of recurrent glioblastoma for the coverage of MET-PET findings in re-radiation therapy planning.

Entities:  

Keywords:  11C methionine positron emission tomography; Glioblastoma; Magnetic resonance imaging; Radiation therapy

Year:  2018        PMID: 29760596      PMCID: PMC5948323          DOI: 10.1016/j.rpor.2018.04.003

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  27 in total

1.  Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma.

Authors:  Nobuyuki Kawai; Yukito Maeda; Nobuyuki Kudomi; Keisuke Miyake; Masaki Okada; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-12       Impact factor: 9.236

2.  Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo.

Authors:  P Heiss; S Mayer; M Herz; H J Wester; M Schwaiger; R Senekowitsch-Schmidtke
Journal:  J Nucl Med       Date:  1999-08       Impact factor: 10.057

3.  Methionine Uptake and Required Radiation Dose to Control Glioblastoma.

Authors:  Toshihiko Iuchi; Kazuo Hatano; Yoshio Uchino; Makiko Itami; Yuzo Hasegawa; Koichiro Kawasaki; Tsukasa Sakaida; Ryusuke Hara
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-05-08       Impact factor: 7.038

4.  Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas.

Authors:  M C Chamberlain; J A Murovic; V A Levin
Journal:  Neurology       Date:  1988-09       Impact factor: 9.910

5.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch
Journal:  J Natl Cancer Inst       Date:  1993-05-05       Impact factor: 13.506

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

7.  Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment.

Authors:  L E Gaspar; B J Fisher; D R Macdonald; D V LeBer; E C Halperin; S C Schold; J G Cairncross
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

8.  Cranial neuronavigation with direct integration of (11)C methionine positron emission tomography (PET) data -- results of a pilot study in 32 surgical cases.

Authors:  V Braun; S Dempf; R Weller; S-N Reske; W Schachenmayr; H P Richter
Journal:  Acta Neurochir (Wien)       Date:  2002-08       Impact factor: 2.216

9.  Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG.

Authors:  R Kubota; K Kubota; S Yamada; M Tada; T Takahashi; R Iwata; N Tamahashi
Journal:  J Nucl Med       Date:  1995-03       Impact factor: 10.057

10.  Prognostic Value of Metabolic Tumor Volume on (11)C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma.

Authors:  Min Young Yoo; Jin Chul Paeng; Gi Jeong Cheon; Dong Soo Lee; June-Key Chung; E Edmund Kim; Keon Wook Kang
Journal:  Nucl Med Mol Imaging       Date:  2015-08-29
View more
  1 in total

1.  MicroRNA-181 inhibits glioblastoma cell growth by directly targeting CCL8.

Authors:  Fengyu Zhai; Xinfeng Chen; Qianyi He; Heng Zhang; Yongqiang Hu; Dan Wang; Shasha Liu; Yi Zhang
Journal:  Oncol Lett       Date:  2019-06-14       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.